Investor Newsletter

Issue 09 2021

MicroPort®

MicroPort® Announces Strategic Investment with Kerui Pharma

MicroPort Scientific Corporation ("MicroPort®") announced that its subsidiary, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort® Shanghai"), entered into an equity acquisition agreement with Fujian 618 Industry Equity Investment Partnership ("618 Fund"), acting in concert with Fujian Tendering Purchasing Group Co., Ltd. ("Tendering Purchasing Group") .

Yiyun Que, Senior Vice President of Intelligent Manufacturing and Supply Chain at MicroPort®, said, "Kerui Pharma is one of the few rapamycin API suppliers in China with NMPA, FDA and CE certifications. Given high quality and state-of-the-art manufacturing techniques, it has become the major rapamycin API supplier for MicroPort® drug-eluting stents over the past 12 years. The investment will enhance the sustainability of MicroPort®'s supply chain management system, leading to the acceleration of the availability of MicroPort® drug eluting stents across markets around the world, allowing MicroPort® to continue to provide trustworthy and universal access to state of the art total solutions that prolong and reshape the lives of patients."

Dr. Seung-Kyun Yue, Senior Vice President of Business Development and Project Management at MicroPort® noted, "As the majority shareholder of Kerui Pharma once the acquisition completes, MicroPort® will remain committed to making sizeable investments in research and development projects and will develop a long-term product strategy for Kerui Pharma, which will guide it to gradually extend its business scope from APIs to pharmaceutical preparation research and manufacturing. Meanwhile, MicroPort®'s existing portfolio of devices, will contribute to a strong synergy with Kerui Pharma, which will unleash tremendous potentials for cooperation in multiple orientations of research and development. Drug-device combination products have the potential to enable safer and more effective treatments and easier or more convenient use by patients, thus significantly improving the performance of any single drug or device alone."

Mr. Zongting Ding, Deputy General Manager of Tendering Purchasing Group and Chairman of the Board of Directors of Kerui Pharma, said, "As the current major shareholder of Kerui Pharma, we are excited for MicroPort® to introduce its modern management system and global resources into Kerui Pharma. Together, we will enhance the capabilities for the development, manufacturing, sales and marketing of innovative drugs. Simultaneously, this will contribute to the high-quality development of the biopharmaceutical and medical device industry in Fujian. "

MicroPort

MicroPort® Acquires German ECLS Company Hemovent® GmbH and Invests in Expansion of German Operations

MicroPort Scientific Corporation (hereinafter referred to as "MicroPort®") announced on October 4th, 2021, through its critical care subsidiary, MicroPort Surgical B.V. ("MicroPort® Surgery"), has acquired 100% of the equity held by existing shareholders of Hemovent GmbH (hereinafter referred to as "Hemovent") for a total cash consideration of up to €123 million. Upon completion of the acquisition, Hemovent will become a wholly-owned subsidiary of MicroPort®.

Mr. Zhiguang Cheng, Senior Vice President of MicroPort® Surgery, said, "Relying on years of expertise accumulated in cardiac systemic circulation, MicroPort® Surgery has been actively expanding its product portfolio into the intensive care field. The light, portable and easy to operate features of MOBYBOX® enable us to expand the application of this innovative ECMO technology to better meet the medical needs in the post-pandemic era. After the completion of the acquisition, MicroPort® Surgery will pursue device internationalization through a US FDA filing and the clinical registration of MOBYBOX® in China, which will provide systematic support centering on clinical needs, so that this innovative product can also benefit Chinese patients as soon as possible."

Mr. Christof Lenz, CEO of Hemovent, said, "We are extremely happy with our new partner MicroPort® who can leverage Hemovent's team efforts with its profound resources, industry expertise and global reach in order to raise our unique technology to the next level. We are looking forward to a significant scale up of business activities in our current Aachen facility, as well as growing our international operations and distribution chains. We trust in our MOBYBOX® system to be an eventual game changer for the application of ECLS, as it offers unrivalled mobility and ease of use in this area of critical care."

Dr. Seung-Kyun Yue, Senior Vice President of MicroPort® Surgery stated, "The products and technologies of Hemovent will complement the current portfolio of critical care solutions of MicroPort®. The 'European Triangle' of R&D and production centers in France, Italy and Germany, is a long term strategic layout of MicroPort® to deeply explore the European market. After completion of the transaction, MicroPort® will focus on strengthening its technology innovation and large-scale industrialization capabilities in Germany, leveraging the synergy of global innovation resources to advance medical technology and save more patients' lives worldwide."

MicroPort® Purchases Property at Heart of Zhangjiang Science City for its Miracle Point Innovation Center for New Materials and Medical Devices

MicroPort Scientific Corporation (00853.HK, "MicroPort®") recently announced that its subsidiary, MicroPort (Shanghai) Scientific Investment Co., Ltd. ("MicroPort® Investment"), has concluded an agreement with Shanghai Huabo Information Services Co., Ltd. and Shanghai Fengjun Enterprise Management Partnership (Limited Partnership), under which MicroPort® Investment will acquire 100% equity interest in Shanghai Huanbo Digital Technologies Co., Ltd. ("Huanbo") for a total consideration of up to RMB 650 million, thereby obtaining full property rights of Huanbo located in Pudong New Area, Shanghai China.

Dr. Hongyan Jiang, Vice President of Research & Development Support and Shared Platform at MicroPort®, said, "The new Miracle Point Innovation Center for New Materials and Medical Devices will serve as a base for operations, research and development, and manufacturing for MicroPort®'s strategic engagement in new bio-pharmaceutical materials, regenerative medicine and other emerging business areas. The bio-pharmaceutical materials platform aims to develop essential medical materials to address the clinical needs of bio-pharmaceuticals and medical devices, and to address the technical challenges of precise and sustained release and long-term biocompatibility of materials. The regenerative medicine platform will focus on solving pressing issues surrounding tissue repair, including bone and cartilage tissue, skin tissue, nerve tissue, and oral cavity, by bringing together innovative technologies in the field of tissue engineering and regenerative medicine. Drug-device combination products hold the potential for delivering safer and more effective therapies and greater convenience or comfort for patients, which could significantly enhance the efficacy of a drug or a device alone. "

"Innovation is one of MicroPort®'s core values," said Mr. Yimin Xu, Executive Vice President of Product Registration and Property Management at MicroPort®. "The acquisition of Huanbo property will, to a certain extent, mitigate the increasingly severe spatial constraint for innovation and industrialization faced by all subsidiaries of the Group in general. We believe that, with the help of governments and communities at all levels, MicroPort® will be able to address the root causes of spatial limitation for its growth in the Yangtze River Delta and even across the country by various means including in-house development, purchasing and leasing. In addition, MicroPort® will continue to focus on independent innovation and make consistent and intensive investments in research and development. We will facilitate the upgrading of synergetic innovation for China's high-performance medical device industry and contribute to the development of Zhangjiang Hi-tech Demonstration Zone while pursuing efficient development and high-quality services to doctors and patients. "

MicroPort® Completes Subject Enrollment for Firesorb® FUTURE-III Pivotal Trial

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), has completed the final subject enrollment for the pivotal FUTURE-III trial of the Firesorb® Bioresorbable Rapamycin Targeted Eluting Coronary Stent System (Firesorb®) – the world's next-generation, fully bioresorbable vascular scaffold system. This milestone marks the completion of the enrollment of all 985 subjects since the first subject enrollment on December 3, 2020.

Ming Zheng, Senior Vice President of Clinical Science at MicroPort®, stated, "The safety and efficacy of Firesorb® in the treatment of primary coronary artery disease is further confirmed by some of the results from previously completed FUTURE trials, which showed rapid early vascular healing, very low incidence of late adverse events and no determined possible device thrombosis using the Firesorb® stent. We look forward to the primary endpoint results of the FUTURE-III project soon, as they will provide even more valuable medical evidence for the clinical practice of coronary intervention."



MicroPort

Products Complete First Implantations in the UK Following Endovastec's Entry into the UK Market

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) announced recently that the first implantations of the Castor® Branched Aortic Stent-Graft System (Castor® Stent), Hercules® Low Profile Thoracic Stent Graft and Delivery System (Hercules®-LP Stent Graft System) and the Minos® Abdominal Aortic Stent-Graft and Delivery System (Minos® Stent Graft System) have been successfully completed in the United Kingdom. The Castor® Stent, Hercules®-LP Stent Graft System and Minos® Stent Graft System are already available in numerous European countries, with their successful usage in the UK further solidifying Endovastec™'s profile in Europe.

The first implantation of the Minos® Stent Graft System in the UK was performed by a team, led by Drs. Duncan Drury and Jon Desiqueira, at the Doncaster Royal Infirmary.

After the procedure, the doctors commented that, "It is the excellent performance of Minos® that made the procedure a success. Its ultra-low profile delivery sheath is able to conform to the shape of the patient's tortuous iliac artery. The system provides an extremely smooth control experience throughout the procedure."

MicroPort

MicroPort® NeuroTech NUMEN Coil Embolization System Approved for Market in Korea

The NUMEN® Coil Embolization System (NUMEN®) and NUMEN FR® Detachment System (NUMEN FR®), developed by MicroPort NeuroTech (Shanghai) Co., Ltd. (MicroPort® NeuroTech), recently received approval for marketing from the Korea Ministry of Food and Drug Safety (MFDS).

NUMEN® and NUMEN FR® have been previously approved for marketing in China and the EU, and in addition, were recently used for the first time in Chile, marking the first implantation in an overseas market.

As one of the most important markets in the Asia-Pacific region, South Korea has an enormous market potential for medical devices. The approval of NUMEN® and NUMEN FR® in Korea will help MicroPort® NeuroTech further penetrate the Korean market.

VitaFlow Liberty™ Completes Implantations across 15 Hospitals on the First Day after Market Launch

MicroPort CardioFlow Medtech Corporation (CardioFlow Medtech) announced on 27 September, 2021, that its VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) was used in surgeries conducted by 19 heart valve teams from 15 hospitals across China on the first day of its market launch. As a next-generation transcatheter aortic valve implantation (TAVI) product, the launch of the VitaFlow Liberty™, initiates a new era of motorized retrievable transcatheters in China's TAVI Market.

Since its launch two years ago, VitaFlow® has become available in more than 250 heart centers in China. The successful implantation of the VitaFlow Liberty™ in clinical centers across China on the first day of its commercial launch shows that it has the potential to improve the surgical experience and deliver a safe, efficient and consistent treatment for surgeons, improving clinical outcomes for patients.

MicroPort

MicroPort® Toumai® Laparoscopic Surgery Robot Becomes First in China to Complete Experimental Sleeve Lobectomy in Animals

The Toumai® Laparoscopic Surgery Robotic System (Toumai®), developed by Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot), has completed its first experimental robotic-assisted sleeve lobectomy in animals. The procedure was carried out by a team, led by Prof. Qingquan Luo, Executive Deputy Director of Department of Oncology, Shanghai Chest Hospital, and is the first sophisticated thoracic procedure performed by a Chinese-developed surgery robot.

Yu Liu, Chief Commercial Officer of MicroPort® MedBot, stated, "Prof. Qingquan Luo is a world pioneer in performing single-port and single-utility-port thoracic surgery using available surgical robot systems. He has developed a new system of robotic surgery approaches, promoted innovations in robotic thoracic surgeries that require fewer ports, and has contributed to the development of minimally invasive lung tumor surgeries in China. MicroPort® MedBot looks forward to strengthening cooperation between doctors and engineers in the future to explore and innovate in the field of minimally invasive surgery, and to jointly introduce more treatment solutions for the benefit of patients."

MicroPort



Chinese-developed Honghu Orthopedic Surgical Robot Completes First 5G Remote Joint Replacement Surgery

Recently, the Honghu Orthopedic Surgical Robot (Honghu), developed by Suzhou MicroPort® OrthoBot Co., Ltd. (MicroPort® OrthoBot) – a subsidiary of Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot) – completed a remote arthroplasty by connecting experts in Shanghai, Kunming and Huizhou with the help of 5G technology. The operation was the first 5G remote joint replacement surgery conducted using a Chinese-developed surgical robot. The remote teams connected via MicroPort® MedBot's 5G interconnectivity platform, which provided real-time high-definition audiovisual transmission throughout the surgery.

Ms. Haiying Yu, General Manager of MicroPort® OrthoBot, remarked, "The launch of 5G technology and the remote surgical support center has improved the consistency of surgical techniques with a much smoother learning curve compared to the traditional approach. It allows surgeons to make customized surgical plans and adjust them flexibly during each operation. The Honghu Orthopedic Surgical Robot not only represents the future direction of precise, intelligent, balanced and optimized remote surgery, but also builds a bridge for doctors to communicate, share and learn from each other. "

MicroPort

Investor Newsletter

Issue 09 2021

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com